Danaher Co. (NYSE:DHR) Shares Sold by BNC Wealth Management LLC

BNC Wealth Management LLC trimmed its position in shares of Danaher Co. (NYSE:DHR) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,101 shares of the conglomerate’s stock after selling 66 shares during the period. BNC Wealth Management LLC’s holdings in Danaher were worth $941,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. acquired a new stake in Danaher in the 4th quarter valued at $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher in the 3rd quarter valued at $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

NYSE DHR opened at $238.41 on Friday. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. The business’s fifty day moving average is $234.85 and its two-hundred day moving average is $253.32.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the company posted $2.02 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, research analysts forecast that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. KeyCorp upped their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Royal Bank of Canada decreased their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research report on Thursday, October 31st. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Stephens reaffirmed an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.